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Effects of hemodialysis and hypertonic hemodiafiltration on cardiac
function compared. This study compared the acute and chronic effects
on cardiac function of treatment with hypertonic hemodiafiltration (H
HDF) and hemodialysis (HD). Cardiac function was assessed before,
during and after a run of H HDF and HD using echocardiography and
impedance cardiography in 10 patients in a randomized cross—over
sequence, two months after stabilization on each treatment. Blood
biochemistry was performed before and after each run. Ejection frac-
tion and fractional shortening were significantly higher before the H
HDF run, compared to the HD run, and this difference persisted during
and after the treatment runs (both P < 0.05). There was a corresponding
significant difference in the increase of the velocity of circumferential
fiber shortening and in the reduction of end systolic diameter during and
after H HDF (P < 0.05). Heart rate, stroke volume, cardiac output,
systemic vascular resistance and mean arterial pressure did not differ
significantly between the two treatments. Plasma calcium and bicarbon-
ate were significantly higher (P < 0.03) at the start of H HDF and this
difference was enhanced at the end of the run. In conclusion, H HDF
compared with HD, is associated with a better myocardial function in
both the short and long term treatments. The evidence suggests that this
may be due to improved levels of plasma calcium, bicarbonate, and/or
the removal of an as yet unidentified myocardial toxin.
Although hemodialysis (HD) is the standard method of solute
removal in patients with chronic uremia, the frequent occur-
rence of side affects such as hypotension has prompted re-
search into alternative methods of management. One such
method is hemodiafiltration (HDF) which is capable of achiev-
ing an efficient removal of water and small and middle mole-
cules from the blood [1]. Recently this technique has been
modified to include simultaneous infusion of a hypertonic
solution which is referred to as hypertonic hemodiafiltration (H
HDF) [2, 31. Clinical observations on patients undergoing this
form of treatment suggest that they experience an enhanced
sense of well-being and an improvement in dialysis tolerance
(4).
The reasons for this improvement remain undefined and may
be due to improvements in one or more of the many pathophysi-
ological features associated with uremia, such as abnormalities
of the cardiovascular and nervous systems. A number of
non-invasive studies, using echocardiography, have examined
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the effects of HD on cardiac function [5, 6]. It has been shown
that in patients with abnormal pre-dialysis end diastolic volume,
a reduction in blood volume after HD resulted in a significant
reduction in the stroke volume, end diastolic volume and left
ventricular ejection time [5]. The end systolic volume was
decreased also, but this change was not significant. Another
report, however, indicated that the effects of regular HD can
lead to improved cardiac function due to a combination of a
decrease in end diastolic volume and an increase in left
ventricular contractility [61. There are no studies on the effects
of H HDF on cardiac function.
A randomized cross—over study was done to examine the
effects of HD and H HDF on cardiac function. Cardiac function
was assessed in terms of changes in stroke volume, cardiac
output, ventricular diameters, ejection time, mean velocity of
fiber shortening, ejection fraction and fractional shortening of
the left ventricle. Cardiac function was studied before, during
and after a treatment run.
Methods
Patients
Thirteen, stable uremic patients at the Incentre Hemodialysis
Unit of the University of Alberta Hospitals volunteered for a
cross—over study which included four months each of HD and
of H HDF in a random sequence. The study had been approved
by the Ethical Review Committee of the University of Alberta
Hospitals.
The criteria for admission to the study were: maintenance
HD for at least six months previously, absence of other
systemic diseases and no clinical evidence of coronary heart
disease, heart failure or pericardial effusion.
The study protocol was completed by 10 out of the 13
patients. Of the drop—outs, one patient underwent kidney
transplantation soon after commencing the study, the second
declined to undergo the cardiac studies and the third dropped
out during his HD control period for personal reasons.
The 10 patients (nine males, one female, mean age 36.5 2.9
SEM years) were on various outpatient medications which were
not changed throughout the study period. One patient had been
prescribed a beta—blocker and another a vasodilator. None
were taking digitalis.
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Table 1. Factors relating to dialysis treatments
Hypertonic hemo-
Factor Standard hemodialysis (N = 10) P diafiltration (N = 10)
Pre-treatment body weight kg 76.5 7.0 76.1 6.8
Body weight loss achieved kg 2.8 0.5 NS 2.9 0.5
Duration of treatment mm 240 0 <0.01 204 10
Weight loss rate glmin 11.5 2.0 <0.01 14.5 2.1
Blood flow rate mI/mm
—250 —400
Dialysate flow rate mi/mm —500
—500
Dializer membrane and surface Cuprophane or Cellulose Acetate (1.1—1.4 m2) Polyacrylonitrile (1.2 m2)
Dialysis solution components mmol/Iiter
Sodium 135.0 135.0
Potassium 1.0 1.0
Calcium 1.55 2.0
Magnesium 0.75 0.75
Chloride 105.6 111.5
Glucose — 11.1
Acetate 35.0 30.0
Bicarbonate 35.0 (1 patient) —
Acetic Acid 2.0 (1 patient) —
Reinfusion solution components ,nmo!/iiter
Sodium — 180 or 220
Chloride — 100 or 120
Bicarbonate — 80 or 100
Means SEM — Student's paired t test.
Treatment methodology
The HD prescription was that deemed appropriate by the
attending nephrologist at each session: the blood flow rate was
—-250 mI/mm; the sodium and the acetate concentration in the
dialysate were 135 and 35 mmol/liter, respectively. One patient
underwent bicarbonate dialysis. Hollow fiber dialyzers
(cuprophane in 9, cellulose acetate in 1), with surface areas
ranging from 1.1 to 1.4 m2 (mean surface area 1.23 m2) were
used.
H HDF consists of a short time, low volume hemofiltration
session (up to a maximum of six liters of postdilution replacing
solution containing sodium at a concentration either of 180 or
220 mmol/liter) run concurrently with acetate HD (Na concen-
tration in the dialysate 135 mmol/liter). The sodium modelling of
H HDF has been described elsewhere [4, 7].
The equipment consisted of a dialysate delivery module in
which a periodically renewed, fresh dialysate circulated in a
predetermined constant volume. Any quantity of liquid re-
moved from this closed circuit, that is, fixed volume, would be
compensated automatically by an equal quantity of fluid ex-
tracted from the patient (Monitral, Hospal, Canada) [8]. The
hypertonic solution was infused in a postdilution site with the
aid of a roller pump (BSM 22, Hospal), the infusion rate of
which could be manually regulated according to the require-
ments of fluid balance. The dialyzer used was the Biospal 3000
S (polyacrylonitrile membrane S, 1.2 m2, Hospal).
Patients maintained their usual treatment schedule (three
times a week) throughout the study. However, the treatment
time was reduced during H HDF by 25 to 30 percent for all, as
it had been previously demonstrated that this reduction in
treatment time could be safely achieved [9]. The characteristics
of the treatment modalities are shown in Table 1.
Three points are emphasized. First, a different blood flow
rate and treatment time was maintained for the HD and H HDF
runs in accordance with our routine practice. Second, for each
patient the loss in body weight was matched and third, all the
dialyses were performed with the same machine (Monitral,
Hospal).
Assessment of cardiac function
Echocardiography. M-mode and two dimensional echocardi-
ograms were obtained using a Diasonic CV6O Echocardiograph
(Diasonics Inc., USA) with the patient in a supine, slightly left
lateral position with the head and thorax elevated at 300 The
phased array transducer (2.25 MHz) was positioned in the left
parasternal position at the 3rd, 4th or 5th intercostal space to
clearly visualize the left ventricle, first along the long axis view
and then rotated 900 to the short axis view. Echocardiograms
were simultaneously recorded with the electrocardiogram (lead
II) on dry silver paper using a strip chart system (Model 4633A
recorder, Tektronix, USA) at 50 mm/sec and on a videocassette
using a videocassette recorder (Model BR6400U, JVC, Tokyo,
Japan) recording M-mode and two dimensional echocardio-
grams, respectively. The transducer was maintained in the
same position and angulation during the run in any one patient.
The two dimensional echocardiogram obtained allowed visu-
alization of the left ventricular structures and accurate measure-
ment of the left ventricular minor axis at the level of the
papillary muscles [10]. The echocardiograph is equipped with
mechanisms for frame by frame analysis and with electronic
calipers for measuring end diastolic and end systolic minor axis
diameters, both in the long and short axis views and an average
of five measurements of each was obtained. End diastolic
diameter (EDD) was measured at the beginning of the R-wave
of the cardiac cycle and end systolic diameter (ESD) at the
smallest dimension observed of the same cardiac cycle. Left
ventricular ejection time (LVET) was measured from M-mode
paper recording of the aortic valve motion. Left ventricular
function was assessed by calculating changes in EDD, ESD,
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ejection fraction: EF = (EDV — ESV)/EDV x 100%, EDV and
ESV calculated according to Teichholz et al [11]; percentage
fractional shortening of the minor diameter: FS = (EDD —
ESD)/EDD x 100%, and mean velocity of circumferential fiber
shortening: VCF (EDD — ESD)/(EDD x LVET) circ/sec.
Impedance cardiography. Stroke volume (SV), heart rate
(HR) and cardiac output (CO) were measured by Impedance
Cardiograph (model 304A, Surcom Inc., U.S.A.). This non-
invasive technique has been evaluated in our laboratory and
found to be accurate and reliable, with a random error of less
than five percent [12, 131. Briefly, this consisted of utilizing four
bands of mylar—backed self—adhesive aluminum electrodes, two
of which were placed around the neck at least 3 cm apart, the
third at the level of the xiphisternum and the fourth at the level
of the umbilicus. A constant sinusoidal alternating current of 4
ma RMS and 100 KHz was passed through the thorax, between
the outer electrodes. The average total impedance (Z0, ohm),
rate of change of impedance (dz/dt, ohm/see) and LVET (sec)
through each cardiac cycle, together with simultaneous electro-
cardiogram and phonocardiogram were obtained while the
patient remained motionless and with the breath held at normal
end-expiration. SV (mi/beat) was calculated from,
SV (P X L2 X dZ/dtmin X LVET)/Z02
where P is resistivity of blood (P =53.2e°°22t), H is hematocrit
(%) obtained from blood samples drawn each time recordings
were made, L is average distance (cm) between the inner pair of
electrodes measured at the midline, anteriorly and posteriorly,
dZ/dtmin = minimum rate of change of impedance occurring
during the cardiac cycle (ohm/see). The SV at each measure-
ment was calculated from an average of five cardiac cycles. CO
was derived from the product of HR and SV of these cardiac
cycles.
Measurement of blood pressure. In order to avoid intra- and
interobserver variations, blood pressure was measured follow-
ing each impedance cardiography recording using an automatic
blood pressure measuring device (Infrasonde D4000, Puritan
Bennet Corporation, USA). Mean arterial pressure (MAP) was
calculated as diastolic plus one—third pulse pressure. Systemic
vascular resistance (SVR) was estimated from the formula: (80
x MAP)/CO where the CO was obtained from the impedance
cardiograms recorded at the same time.
Biochemistry
Blood was drawn for biochemical and gas analysis just before
and after a treatment run. Blood urea nitrogen, plasma creati-
nine, calcium, protein, albumin, glucose, sodium, potassium
and chloride were determined with routine automated methods;
plasma osmolality was measured using the freezing point de-
pression method. Blood gases were analyzed with a Corning
178 gas analyzer.
Experimental protocol
The assessment of cardiac function was performed just
before, during and immediately after a treatment run. Each
patient underwent two assessments, once during the four
months of the H HDF treatment and once during the four
months of the HD treatment. A period of "stabilization" on
each procedure was allowed and studies were conducted 59
12 days after the start of H HDF and 64 12 days after the start
of HD, respectively. In addition to pre- and post-treatment
measurements, echocardiography was performed three times,
and impedance cardiography and blood pressure measurements
six times at equal time intervals during the treatment run.
During a three hour run, echocardiography was done every 60
minutes and impedance cardiography and blood pressure mea-
surements made every 30 minutes. These intervals were in-
creased to 80 minutes and 40 minutes, respectively, during a
four hour run. This allowed the comparability of results despite
the different treatment times.
Echocardiograms and impedance cardiograms were analyzed
without knowledge of which type of dialysis treatment was
under study.
Statistical analysis
A factorial analysis was employed for purposes of comparing
multiple measurements, that is, echocardiography and imped-
ance cardiography results, during a treatment run and compar-
ing the two treatment modalities. Where the results of the
factorial analysis were significant, the difference between
means was detected by a Least Significant Difference test [141.
A paired Student's t-test was used in the case of biochemical
and gas analysis where only pre- and post-treatment measure-
ments were made. In both instances a P < 0.05 was accepted as
statistically significant, Results were expressed as means
SEM.
Results
The 10 patients completed four months each with HD and H
HDF without experiencing hypotension. Treatment sessions
were three times per week. At each treatment session, the
duration for treatment was decided by the attending nephrolo-
gist. Over each of the four month periods, treatment duration
for H HDF ranged from 180 to 240 minutes, with a mean of 206
9 minutes; and for HD it ranged from 240 to 360 minutes with
a mean of 285 14 minutes. Besides the blood biochemistry
evaluation as performed for this study, monthly measurements
of blood biochemistry to monitor the patients' nutritional status
were done. In each case blood was taken before the midweek
treatment run for this purpose. Consecutive monthly plasma
albumin levels while the patients were on H HDF were 42.9
1.6 g/liter, 41.2 0.9 g/liter, 42.7 0.9 g/liter and 42.3 1.1
g/liter, and while on HD they were 42.9 1.2 glliter, 43.8 1.2
glliter, 43.3 1.4 glliter and 42.1 0.8 g/liter. The correspond-
ing hematocrit levels were 27.0 1.1%, 26.9 1.4%, 27.4
1.3% and 26.1 0.9% for H HDF, and 26.2 1.0%, 27.3
1.1%, 27.1 1.1% and 26.7 1.5% for HD. Plasma transferrin
levels for H HDF during the first, second and fourth month
were 2.6 0.2 glliter, 2.6 0.2 g/liter and 2.5 0.1 glliter,
respectively; for HD, they were 2.4 0.2 g/liter, 2.6 0.1
g/liter and 2.4 0.1 g/liter. No significant inter- or intra-
treatment differences were found in the plasma albumin, trans-
ferrin and hematocrit. During the four month treatment periods
mean blood urea nitrogen before the treatment runs was 29.1
0.7 mmol/liter for H HDF and 29.2 0.6 mmol/liter for HD.
The corresponding plasma creatinine levels were 1283 26
mol/liter for H HDF and 1265 13 prnol/liter for HD. There
were no significant intra-treatment differences in these levels of
blood urea nitrogen or plasma creatinine.
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Echocardiography
In the pre-treatment phase, there was no significant different
in ESD and EDD between the two methods of treatment.
During and immediately after treatment with H HDF (when the
blood in the dialyzing system had been returned to the patient),
a significant decrease in ESD was noted. The last three of the
total of five measurements were significantly lower than the
initial two (P < 0.05). Also, these three values were signifi-
cantly lower than those obtained in patients on RD (P <0.05).
With HD, there was a gradual decrease in ESD also but this
change was not statistically significant (Fig. 1A).
There was a trend towards a smaller EDD with both H HDF
and HD but no statistically significant differences could be
demonstrated between the two methods or during sessions on
each type of treatment (Fig. IB).
No significant difference in LVET was found between the
patients on the two methods of treatment before the session.
LVET decreased gradually as treatment proceeded and the
trend towards a shorter ejection time was more obvious with H
HDF than with RD (Fig. lC). These differences were not
significant.
In the pre-treatment phase, the mean VCF was not signifi-
cantly different in patients treated by the two methods. How-
ever, a significant increase in mean VCF was found with H
HDF during the session, the last three of the five measurements
being consistently higher than the first two (P < 0.05). These
values were higher than the corresponding values when the
patients were on HD (P < 0.05). With HD there was a similar
trend but only the measurement at the end of treatment was
significantly higher than the others (P < 0.05) (Fig. lD).
Both EF and FS were significantly higher when the patients
were on H HDF than when they were on HD before a treatment
session and this difference was maintained during and after
completion of the session (both P <0.05).No significant trends
were seen in either EF or FS during the two sessions on the two
methods (Fig. 1, E and F).
Impedance cardiography
HR, SV and CO before treatment were similar when the
patients were on either H HDF or HD. During treatment with
either method, there was a trend towards a smaller SV and
higher HR, but none attained statistical significance (Fig. 2A
and B). With H HDF, there was a tendency towards a greater
SV and a slower HR when compared with RD but no statistical
significance could be demonstrated. CO remained unchanged
(Fig. 2C). On completion of treatment, after the blood in the
dialysis system has been returned to the patients, there was a
sudden increase in SV, (tending to return the SV to pre-
treatment levels) associated with a decrease in HR and an
increase in CO. This increase in SV was again more obvious
with H HDF than with HD but did not attain statistical
significance.
A small, inconsistent and statistically insignificant decrease
in MAP was noted during treatment (Fig. 3A). Similarly, an
inconsistent trend towards a reduced SVR was found (Fig. 3B).
Tables 2 and 3 summarize the results of the echocardiography
and impedance cardiography measurements.
Treatment
Fig. 1. Comparison of echocardiographic parameters between H HDF(•—•)andHD (•---•) before (Pre), after (Post) and3 times during
treatment at equal time intervals. Abbreviations are: ESD, end systolic
diameter; EDD, end diastolic diameter; LVET, left ventricular ejection
time; VCF, mean velocity of circumferential shortening; EF, ejection
fraction; FS, fractional shortening. (*) in A indicates that the last 3
measurements of ESD with H HDF were significantly lower (P < 0.05)
than the initial 2, and all 5 measurements with HD. (**) in D shows that
the last 3 mean VCF were significantly greater (P < 0.05) than the initial
2 with H HDF and the corresponding measurements when patients
were on HD. (***) in D indicates that this mean VCF was significantly
greater (P < 0.05) than the other 4 measurements with HD. (****) in E
and F shows that EF and FS during H HDF were significantly greater
(P < 0.05) than with HD befbre treatment, and this difference was
maintained throughout the treatment run, with no intra-treatment
differences found with either H HDF or HD. All values are expressed
as means SEM. Comparisons were made using a factorial analysis.
Biochemistry
Plasma calcium and bicarbonate at the start of the treatment
runs were higher in H HDF than in HD. This difference was
4.0 A
3.5
3.0
w
2.5
5.0 B
4.5
4.0
3.5
0.35 C
0.30
0.25
0.20
1.5 D
1.4
1.3
1.2
1.1
U-0> 1.0
0.9
0.8
60 E
56
52
48
44
32 F
30
28
26
24
22
Discussion
Study design
Fig. 3. Comparison of mean arterial pressure (MAP) and systemic
vascular resistance (SVR) between H HDF •—S) and HD (•---•)
before (Pre), after (Post) and 6 times during treatment at equal time
intervals. No significant intra and inter-treatment differences were
found using a factorial analysis. All values are expressed as means
SEM.
studied approximately two months after they had started on H
HDF or HD to allow for stabilization with the assigned method.
I —i Any changes observed between groups in the pre-treatment
5 6 Post phase of each session were designated chronic effects. Exami-
nations were also carried out during the treatment session to
obtain a profile of acute changes in cardiac function. This design
differed from those of previous studies relating to cardiac
function during dialysis in several important aspects [5, 6,
15—181.
Cardiac function was assessed sequentially during an entire
session. All the tssessments were done noninvasively [19], and
finally, a two-month stabilization period was used in this study
to permit equilibration of the patients. Impedance cardiography
was used to assess SV and CO as it was felt that this technique
offered greater accuracy and reproducibility of the results, as
previously reported from this laboratory [12, 131. Due to the
different treatment times in HD and H HDF and to allow for
comparability of the results, an equal number of measurements
at equal intervals during dialysis were made, the duration of the
intervals being dependent on the actual dialysis time required
for each patient. Assuming that the rate of fluid loss was more
or less constant during either procedure, comparisons could be
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Fig. 2. Comparison of stroke volume, heart rate and cardiac output
between H HDF (•—I) and HD (---•) before (Pre), after (Post)
and 6 times during treatment at equal time intervals. No significant
intra and inter-treatment differences were found, using a factorial
analysis. All values are expressed as means SEM.
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enhanced at the end of the run. Further, plasma glucose,
sodium, osmolality and PaCO2 at the end of the run were
significantly higher in H HDF than in HD (Table 4).
This study was undertaken to evaluate the 'acute' and
'chronic' effects of H HDF on cardiac function in a group of
relatively young patients without evidence of coronary heart
disease, heart failure or pericardial effusion. Patients were
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Table 2. Cardiovascular data derived from echocardiography in ten patients before, during and after a run of hypertonic hemodiafiltration
(H HDF) and a run of hemodialysis (HD)
ESD cm EDD cm VCF circisec EF %C FS %C
Normal range 2.0—3.4 3.7—5.6 LVET sec' 1.02—1.94 55—84 25—42
Pre-treatment
H HDF 3.33 0.21 4.58 0.23 0.290 0.012 0.943 0.035 53.1 2.8 27.5 1.8
HD 3.41 0.20 4.52 0.21 0.277 0.011 0.904 0.054 48.9 2.7 24.9 1.6
During treatment
#1 H HDF 3.22 0.22 4.44 0.23 0.263 0.015 1.072 0.044 54.4 2.6 28.1 1.7
HD 3.33 0.23 4.34 0.21 0.244 0.011 1.025 0.070 48.1 3.5 24.9 1.8
#2 H HDF 2.95 0,21b 4.18 0.24 0.221 0.019 1.355 0.070c 56.6 2.5 29.7 1.8
HD 3.23 0.22 4,25 0.23 0.226 0.010 1.083 0.051 48.3 2.7 24.4 1.4
#3 H HDF 2.88 0.23' 4.01 0.22 0.208 0.019 1.407 0.085c 54.4 3.1 28.7 2.5
HD 3.08 0.21 4.16 0.21 0.211 0.013 1.272 0,117d 51.1 3.4 26.3 2.4
Post-treatment
H HDF 3.00 0,20b 4.17 0.22 0.229 0.017 1.226 0.044' 54.9 3.1 28.2 1.7
HD 3.22 0.17 4.28 0.19 0.236 0.013 1.06 0.335 47.7 3.4 24.8 1.9
a Varies inversely with heart rate
b Significantly < initial 2 measurements with H HDF and all 5 with HD (P < 0.05)
C Significantly> initial 2 measurements with H HDF and the corresponding measurements with HD (P < 0.05)
d Significantly > the other 4 measurements during HD (P < 0.05)
C EF and FS with H HDF> with HD before, during and after the treatment run (P < 0.05)
Table 3. Cardiovascular data derived from impedance cardiography in ten patients before, during and after a run of hypertonic
hemodiafiltration (H HDF) and a run of hemodialysis (HD)
HR SV CO MAP SVR
beats/mm mi/heat liter/mm mm Hg dynes ' sec ' cm5
Pre-treatment
H HDF 71.8 4.4 98.2 9.6 6.91 0.68 94.4 6.7 1238 186
HD 73.7 3.4 93.1 8.3 6.79 0.88 94.7 6.1 1190 100
During treatment
#1 H HDF 75.3 3.8 85.3 9.2 6.43 0.79 97.5 6.8 1412 215
HD 80.1 4.5 82.4 7.9 6.63 0.80 98.5 5.6 1361 162
#2 H HDF 76.4 4.3 85.1 6.4 6.49 0.60 96.5 6.2 1302 144
HD 86.6 4.0 75.5 6.4 6.73 0.66 94.7 5.5 1280 177
#3 H HDF 81.6 5.5 83.8 7.3 6.82 0.76 90.7 5.2 1225 167
HD 88.6 5.0 73.1 6.2 6.35 0.50 93.5 5.7 1262 117
#4 H HDF 88.0 5.6 72.2 6.6 6.39 0.77 90.8 6.0 1298 147
HD 93.5 6.2 71.0 7.0 6.41 0.51 91.0 6.1 1228 132
#5 H HDF 89.8 6.4 76.2 6.9 6.64 0.55 91.3 6.1 1177 112
HD 93.1 5.8 65.5 7.0 5.92 0.55 90.3 7.4 1333 158
#6 H HDF 94.9 7.6 70.6 8.3 6.36 0.58 89.5 5.6 1247 150
HD 94.0 6.2 68.2 7.2 6.18 0.69 95.3 5.5 1404 203
Post-treatment
H HDF 87.7 6.0 91.7 8.9 7.80 0.68 90.7 3.8 1023 94
HD 89.4 4.6 76.5 7.9 6.79 0.62 96.3 5.9 1230 119
Note: For each parameter, no inter- or intratreatment differences were found.
made at each interval point despite the different treatment
times.
Ventricular function
The changes in ventricular function with both HD and H
HDF were similar to earlier studies with HD in that there was
a decrease in EDD, ESD and LVET and an increase in mean
VCF [5, 6, 15]. The finding that EF and FS did not change
significantly was also noted previously [18]. Contrary to some
reports [5, 61 a significant decrease in EDD was not found
during HD in this study. However, this apparent discrepancy
could have arisen because of the type of statistical analysis
employed. In the earlier reports [5, 15], measurements were
made before and after a treatment session, and the authors
rightly used a paired t-test to compare the results. In the present
study, since multiple observations involving two forms of
treatment were made, a factorial analysis incorporating an
analysis of variance was thought to be a more appropriate test
of statistical significance. Indeed, if one were to compare only
the observations made before and after the treatment session
using a paired t-test, a highly significant decrease in EDD could
be demonstrated in both HD (P < 0.025) and H HDF (P <
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Table 4. Biochemical data in ten patients before and after a run of hypertonic hemodiafiltration (H HDF) and a run of hemodialysis (HD)
PRE POST
HHDF HD HHDF HD
Blood urea nitrogen mmoll/iter 29.1 2.7 29.9 2.5 12.3 1.5 12.5 1.5
Plasma creatinine ,amollliter 1340 78 1326 87 628 51 646 64
Plasma calcium mmol/liter 2.28 0.05C 2.2! 0.04 2.99 0.05C 2.70 0.08
Plasma protein glliter 65.9 0.9 65.7 1.4 81.8 2.! 79.7 3.5
Plasma albumin glliter 39.9 1.0 39.7 1.3 50.2 1.4 48.9 2.2
Plasma glucose mmollliter 5.2 0.4 6.1 0.5 7•3 Ø•4c 5.5 0.4
Plasma sodium mmollliier 139.7 0.7 138.4 0.3 140.8 10b 136.9 1.0
Plasma potassium mmol/Iiter 5.5 0.4 5.1 0.3 3.0 0.1 3.2 0.2
Plasma chloride mmo/Iliter 103.4 0.8 104.7 0.6 lOl.0 0.7 101.8 0.5
Plasma osmolality mmollkg H,O 312.6 2.8 313.0 2.8 298.4 27b 288.3 3.8
Arterial P02 mm Hg 87.5 4.2 91.4 2.9 82.2 2.1 89.3 4.6
Arterial PCO2 mm Hg 35.2 1.5 32.0 1.2 32.5 13b 28.5 1.0
Arterial [H] nmol/liter 40.5 0.6 44.1 1.9 33.8 0.8 35.5 0.9
Arterial bicarbonate mmol//iier 20.9 0.9k' 17.6 0.7 23.1 09b 19.3 0.7
All values are expressed as means SEM.
a P < 0.03; bP < 0.01; C P <0.001, Students's paired 1-test
0.005) in the present study. The same could also be demon-
strated for LVET in both HD (P < 0.005) and H HDF (P <
0.001) as well as for SV (both, P < 0.05).
A number of distinct features associated with H HDF as
compared to HD are emphasized. While there was a similar
trend towards a smaller EDD and shorter LVET as treatment
proceeded with both H HDF and HD, ESD became signifi-
cantly smaller only when the patients were on H HDF, This
significant decrease in ESD was reflected in an enhancement of
the increase in mean VCF, especially during the second half of
the treatment session. The increase in VCF found in the
patients while on HD was similar to that reported by others [5,
6, 15, 161. However, at corresponding points of assessment
during treatment, the VCF was higher with H HDF than with
HD and this difference reached statistical significance in the last
three measurements. These findings suggest that while acute
improvements in left ventricular function occurred with both
forms of treatments, H HDF was associated with a bigger
improvement.
Further, it has been suggested that decreases in end systolic
parameters such as end systolic volume are sensitive indicators
of myocardial function, especially in the absence of significant
changes in cardiac pre-load, afterload or heart rate [201. It may
therefore be suggested that the significant decreases in ESD
noted in this study offers a further indication that H HDF was
associated with a greater acute improvement in ventricular
function during the treatment run.
There were significant increases in EF and FS in the pre-
treatment phase of each session when the patients were on H
HDF than when they were on HD. These differences were
observed before any changes in pre-load and afterload that may
have occurred during the sessions. Also, these differences were
maintained during the treatment runs with no significant intra-
treatment differences during either H HDF or HD. Such a
finding could suggest a chronic effect due to the treatment
modality, particularly as the patients had undergone an average
of two months of either H HDF or HD before the study was
made.
It is of interest to note the apparent discrepancy between
these changes in EF and FS and the changes noted with ESD
and VCF. These findings have some features in common with
the report by Chaignon et al [18] who showed that there were no
significant alterations in EF and FS during dialysis, but VCF
increased significantly in patients so treated. It is generally
accepted that EF, FS and VCF reflect the basal contractile state
of the ventricle [21]. During dialysis, there are shifts in fluid
volume and simultaneous changes in pre-load and afterload. It
has been suggested that these indices may be affected second-
arily by such changes and that the differences observed are not
indicative of changes in contractility per se [22, 23]. However,
Ross [24] concluded that when both pre-load and afterload were
simultaneously increased or decreased, mean VCF remained
nearly constant. Indeed, Chaignon et al suggested that mean
VCF might be more sensitive than EF as an index to follow
changes in cardiac function during dialysis [18].
In the present study, MAP and SVR, reflecting afterload, did
not change significantly during treatment with both methods.
There was no difference also between the forms of treatment.
EDD, which reflects pre-load [25], decreased during both
treatments, though not significantly. With H HDF, as compared
with HD, there was a significant decrease in ESD and a greater
(but not significant) decrease in LVET. The combination of
these two factors contributed to a greater change in mean VCF
with H HDF, With EF and FS, which are not related to LVET,
such differences were not evident. These considerations could
explain why EF and FS did not change significantly during a
treatment run in this study or in that of Chaignon et a! [18].
LVET has been shown to vary inversely with heart rate [26]. In
this study, a trend towards a shorter LVET with H HDF was
noted despite a slower heart rate at each point of assessment. It
is suggested that this change reflects an improvement in
ventricular function also.
The CO did not change significantly during treatment with
either H HDF or HD. These findings are comparable to those
reported by Mansel! et al [27] who compared intra-dialysis
changes of CO in patients with high or normal blood acetate
levels. They observed also that in the group of patients with
steady acetate levels during HD, there was a gradual but not
significant decrease in CO, which then returned to near pre-
dialysis level on completion of dialysis following return of the
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blood contained in the dialyzer to the patient. In the present
study it was found that the changes in CO were due mainly to
the gradual decrease in SV and that this change was compen-
sated partially by a gradual rise in HR.
There was a modest trend towards a greater SV and slower
HR with H HDF when compared with HD, though this change
was not significant. During treatment with either method, there
was a gradual but statistically insignificant drop in SV and
increase in HR. Leenen et at [171 also found the same trend
during HD. Significant decreases in SV accompanied by hypo-
tension were noted by Mansell et al [271. A significant decrease
in MAP was not found in the present study probably due to the
absence of a significant reduction in SV during treatment.
In summary, the results of the present study are consistent
with the findings that improved myocardial contractility was the
major contributing factor in the improved cardiac function
associated with H HDF.
Equivalence of HD and H HDF treatments
It is possible that the differences in ventricular function that
were found could be due to differences in the solute transport
characteristics of these two different treatment methods. Ki-
netic modelling of small molecules (urea, creatinine) was not
used to define adequacy or equivalence of these treatment
methods. The pre-treatment levels of urea and creatinine were
similar. In the "long term" studies which involved a four—
month treatment period, the following nutritional parameters
were also similar: albumin, transferrin and hematocrit. In
addition, the routine clinical assessment of these patients found
them to be adequately dialyzed and nutritionally unchanged. It
was concluded, because of the above considerations, that these
treatment methods were comparable and that the differences in
ventricular function were not due to a more adequate treatment
provided by H HDF.
Biochemical factors
Significant increases in plasma calcium and bicarbonate were
found when the patients were on H HDF before a treatment
session and these differences were enhanced at the end of the
run when compared with the results when the patients were on
HD. There is some evidence to suggest that these findings may
have a role to play in the improvement of cardiac function with
H HDF.
Chaignon et a! [18] postulated that an improvement in left
ventricular function may be due to an increase in intra-dialytic
serum calcium and a concomitant decrease in serum potassium
concentration. Similar results were reported by Henrich, Hunt
and Nixon [28] who showed a positive correlation between
increasing intra-dialytic plasma, ionized calcium levels and
improved left ventricular function. It is of interest to note that
pre-treatment plasma calcium levels were significantly higher
when our patients were on H HDF than when they were on HD,
due to a more positive calcium balance. Further, while calcium
levels were increased following dialysis with both methods, the
difference in calcium concentration between the two treatment
modalities was at a higher level of significance. This difference
may explain the greater improvement in left ventricular func-
tion associated with H HDF, both over the long and the short
term. However, the mechanism for this improvement remains
unclear and needs further evaluation. For example, the role of
calcium may be studied using different calcium concentrations
in dialysates in experiments similar to the present study.
Experimental studies have shown that metabolic acidosis can
decrease cardiac contractility [29, 30]. Smith et al [31] pointed
out, however, that the depressive effects of metabolic acidosis
were considerably less than suspected. Furthermore, the in-
crease in plasma bicarbonate levels during dialysis did not
improve ventricular contractility in the study by Henrich et at
[28]. Thus, the evidence for increased levels of plasma bicar-
bonate, as found in this study, as a factor for the improved
cardiac function appears less clear.
In summary, this study shows that H HDF, compared with
HD, is associated with a better myocardia! function, both in the
short and long term. There is some evidence that plasma
calcium levels may play a role in causing this improvement.
Other factors, for example a significantly higher plasma
osmolality, was noted in this study to be associated with H
HDF. This change in osmolality could be involved in preserving
the plasma volume more efficiently during treatment with H
HDF and indirectly influencing ventricular function, and it is
suggested that additional studies are needed to investigate this
aspect. It is suggested also that during treatment with H HDF
further experiments should be performed to examine the effects
of H HDF on ventricular function in protocols where patients
are treated without a change in weight. Finally, the improve-
ment in ventricular function may be due to the more efficient
removal by H HDF of an as yet unidentified myocardial toxin
[32].
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